Releviate

Shutdown

Website unreachable since Oct 29, 2026

This company develops human monoclonal antibody therapies to treat neuropathic pain by targeting and inactivating specific matrix metalloproteinases. Their approach offers an alternative to opioids by addressing the underlying causes of chronic pain.

Traction –/10

HQ unknown

Biotechnology

Updated 5 months ago

Funding

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Features

This company develops human monoclonal antibody therapies to treat neuropathic pain by targeting and inactivating specific matrix metalloproteinases. Their approach offers an alternative to opioids by addressing the underlying causes of chronic pain.